Devices/Safety Alert·FDA MedWatch Safety Alerts

Disruptions in Availability of Neurosurgical Patties, Sponges, and Strips - Letter to Health Care Providers

MediumPublished May 6, 2026· AI-analyzed May 10, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA issued a Letter to Health Care Providers regarding a supply disruption for Neurosurgical Patties, Sponges, and Strips identified by product code HBA.

Who it affects

This affects neurosurgical departments, surgical staff, healthcare procurement professionals, and manufacturers of neurosurgical patties, sponges, and strips under product code HBA.

Why it matters

A disruption in these essential surgical materials may require facilities to reassess surgical schedules or seek alternative supplies to maintain standard of care in neurosurgical procedures. The FDA notification suggests that the shortage is significant enough to warrant formal communication to the clinical community, potentially indicating a widespread impact across the product class.

Practical takeaway

Clinical and procurement teams should evaluate current inventory levels of HBA-coded neurosurgical materials. Regulatory and supply chain departments should monitor for further FDA updates regarding the duration of the disruption and potential alternative suppliers or products.

FDA source material

The FDA issued a LHCP to notify providers that Neurosurgical Patties, Sponges, and Strips (product code HBA) are experiencing a supply disruption.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.